ALL OR	DERS MUST BE SIGNED, I	DATED AND TIMED BY	PHYSICIAN	
Allergies/Reactions:			9	ion Services - Fax: 253-530-8069
	☐ Allenmore Ambulatory Infusion	Services - Fax: 253-864-4052	DHEC Infusion Co	enter - Fax: 509-755-5845
	☐ Auburn Infusion Services - Fax	: 253-876-8282	☐ North Spokane Ir	nfusion Center - Fax: 509-232-2531
ORDERS WITH CHECK BOXES When an order is optional (those with check boxes), physicians are responsible for indicating a check mark in the box next to the order. Orders left unchecked will not be initiated.				
Osteoporosis Treatments				
Patient Name:		Requ	uested Date of Se	rvice:/
Date of Birth:/P	atient Phone Number: () ICD -10 Code:	\ Mo	ay leave message
Diagnosis: □ Osteoporosis				
☐ Osteopenia				
☐ Other		U		
Required: H&P with documentation to support above diagnosis including ICD-10 code and supporting labs. Dexa scan is recommended every 2 years.				
If required documentation not received with order, scheduling of treatment will be delayed until complete information is available				
Baseline labs required: • BMP				
Serum Calcium mg/dL				
Contraindicated to give denosumab, romosozumab-aqqg or bisphosphanates in patients with hypocalcemia				
Serum Creatinine mg/dL Contraindicated to give zoledronic acid if CrCl <35 mL/min, or ibandronate if CrCl <30 mL/min				
Annual Vitamin D level (25-hyroxyvitamin D)ng/mL (Zoledronic Acid, Ibandronate)				
Maintenance labs required: Serum Creatinine (q3 months for ibandronate, q6 months for denosumab and romosozumab-aqqg, q12 months for zoledronic acid) Serum Calcium every 6 months for denosumab, ibandronate OR romosozumab-aqqg; every 12 months for zoledronic acid Vitamin D level (25-dyroxyvitamin D) every 12 months (Zoledronic Acid, Ibandronate)				
☑ IV Access: Access and/or maintain IV site in accordance with MHS IV Therapy P&P: Peripheral IV Device Site Selection, Insertion, Maintenance, and Discontinuation; and Maintenance of Central Venous Catheters-Flushing, Dressing Changes and Removal.				
Treatment Regimen: □ Denosumab (Prolia) 60 mg SQ every 6 months x 1 year □ Zoledronic Acid (Reclast) 5 mg IV infusion over at least 15 minutes x 1 dose • Recommended to have patient hold furosemide or torsemide morning of infusion □ Ibandronate (Boniva) 3 mg IV push over 30 seconds every 3 months x 1 year • Recommended to have patient hold furosemide or torsemide morning of dose □ Romosozumab-aqqg (Evenity) 210 mg (administered as 2 injections) SQ every month x 12 doses • Contraindicated in patient with history of stroke or myocardial infarction within the preceding year				
☑ Vital Signs: Check vital signs prior to dose. Contact provider if systolic BP >180; diastolic BP >100; systolic BP <90; HR >110; temp >38C (100.4F)				
If hypersensitivity develops (fever, chills, hypotension, rigors, itching, rash, etc.): • Consult MultiCare hypersensitivity guideline for treatment management • Notify provider of reaction, assessment and need for futher orders				
Code Status: Please note, patients will be considered FULL Code unless marked otherwise. If the patient has a POLST, advance directive or living will, please include a copy with the orders.				
Was consent obtained: ☐ Yes ☐ No (if yes, please send DOCUMENTATION of consent with order)				
Provider Signature	Print Name		Date	Time
Another brand of drug, identical in form and a	content, may be dispensed uply	ass chacked \square	Orders eyn	ire in 12 months**
Another brand of arug, identical in form and c			Orders exp	II TT HOURTS

Name:

MRN #:

CSN #:

Age / Sex and Gender:

Pre-printed Order **OSTEOPOROSIS TREATMENTS**

MultiCare 🕰

